DoW Adds $3.3 Million to MediWound’s NexoBrid Development Program

The U.S. Department of War (DoW) announced an additional $3.3 million award to MediWound Ltd. on November 12, 2026, supporting development of a room-temperature-stable formulation of NexoBrid for battlefield burn care. The additional funding brings the program budget to $21.8 million. The formulation effort is intended to continue through submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a development milestone rather than a product procurement opportunity.

The award is relevant to defense medical readiness and suppliers working in burn treatment, pharmaceutical formulation, and medical countermeasures. A room-temperature-stable formulation could address storage and handling considerations in operational settings, although the source does not provide technical specifications, a fielding timeline, or details about any eventual production requirement. Companies should therefore treat the announcement as evidence of continued development investment, not as confirmation of a forthcoming production contract or open competition.

The development award is separate from Biomedical Advanced Research and Development Authority (BARDA)-related NexoBrid product purchases routed through Vericel’s contract. Those purchases began in the third quarter of 2026 and are expected to continue through the first quarter of 2027. The available information identifies these as existing purchasing activity; it does not announce a new solicitation or disclose purchase quantities, values, or a new award action for suppliers to pursue.

MediWound’s commercial and financing context also bears watching. Its quarterly revenue declined year over year from $5.4 million to $3.6 million, with the decrease attributed to lower U.S. government development-services revenue. The company has also described discussions with the U.S. government about funding a planned U.S. manufacturing facility, but the timing and outcome remain uncertain. As MediWound Chief Executive Officer Ofer Gonen stated: “We are also working diligently with the U.S. government to secure funding for our planned U.S. manufacturing facility. The timing and outcome of these funding discussions remain uncertain.” For contractors and suppliers, the distinction among funded development, product purchases under an existing contract, and unresolved facility funding is important when assessing near-term pipeline and potential future capacity requirements.

• DoW added $3.3 million for development of a room-temperature-stable NexoBrid formulation for battlefield burn care.
• The additional award brings the reported program budget to $21.8 million.
• Development is intended to continue through an IND application to the FDA; the source does not give a submission date.
• BARDA-related NexoBrid purchases through Vericel’s contract began in Q3 2026 and are expected to continue through Q1 2027.
• The reported award and purchases are existing activities, not an open solicitation or newly announced competition.
• MediWound’s quarterly revenue fell year over year from $5.4 million to $3.6 million, attributed to lower U.S. government development-services revenue.
• Funding discussions for MediWound’s planned U.S. manufacturing facility remain uncertain; no facility funding amount or timing was disclosed.
• Relevant market participants include medical countermeasure developers, formulation and manufacturing suppliers, and firms monitoring federal burn-care purchasing activity.